Chengdu Institute of Biological Products Co.,Ltd.
11
1
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
82%
9 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging
Role: collaborator
A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
Role: collaborator
Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population
Role: collaborator
Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4
Role: collaborator
Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP
Role: collaborator
Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
Role: collaborator
A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
Role: collaborator
Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4
Role: collaborator
Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4
Role: collaborator
Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR
Role: collaborator
Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults
Role: collaborator
All 11 trials loaded